Madrigal Pharmaceuticals, Inc. (MDGL)
NASDAQ: MDGL · Real-Time Price · USD
327.70
-6.21 (-1.86%)
May 1, 2025, 4:00 PM EDT - Market closed
Madrigal Pharmaceuticals Revenue
Madrigal Pharmaceuticals had revenue of $137.25M in the quarter ending March 31, 2025. This brings the company's revenue in the last twelve months to $317.38M. In the year 2024, Madrigal Pharmaceuticals had annual revenue of $180.13M.
Revenue (ttm)
$317.38M
Revenue Growth
n/a
P/S Ratio
22.50
Revenue / Employee
$601,104
Employees
528
Market Cap
7.24B
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.19B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.90B |
MDGL News
- 14 hours ago - Madrigal Pharmaceuticals, Inc. (MDGL) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 20 hours ago - Madrigal Pharmaceuticals Reports First-Quarter 2025 Financial Results and Provides Corporate Updates - GlobeNewsWire
- 2 days ago - Madrigal to Present Late-Breaking Resmetirom Data in Patients with Compensated MASH Cirrhosis at the EASL Congress - GlobeNewsWire
- 13 days ago - Madrigal Pharmaceuticals to Release First-Quarter 2025 Financial Results and Host Webcast on May 1, 2025 - GlobeNewsWire
- 15 days ago - Madrigal Pharmaceuticals Announces Company Founder Rebecca Taub, M.D. to Become Senior Scientific and Medical Advisor; David Soergel, M.D. - GlobeNewsWire
- 7 weeks ago - Madrigal Appoints Jacqualyn A. Fouse, Ph.D. - GlobeNewsWire
- 2 months ago - Madrigal Pharmaceuticals: Rezdiffra First-Mover Advantage Gains Traction (Upgrade) - Seeking Alpha
- 2 months ago - Madrigal Pharmaceuticals Stock Jumps On New Two-Year Data Showing Potential Benefit of Rezdiffra For Compensated Fatty Liver Cirrhosis - Benzinga